Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Go to homepage

We want to hear from you!

Find out

How we can help you address your challenges.

Explore opportunities

From collaborations to careers.

Get in touch

For partnerships, press, and everything else.

If you have a question, request, or you just want to learn more about the role of digital twins in the healthcare industry, contact us. We’d love to hear from you.

ELEM works with pharmaceutical companies, CROs, researchers, and healthcare innovators to advance the use of biosimulation across the drug development pipeline.